Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 2Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell 1Lymphoma 1Hematologic Diseases 1

Interventions

Carboplatin 18Cisplatin 14pembrolizumab 13durvalumab 11Pemetrexed 11Paclitaxel 11Nivolumab 11Gemcitabine 11Rituximab 9trastuzumab deruxtecan 7osimertinib 6olaparib 6Dexamethasone 6Capecitabine 6atezolizumab 5acalabrutinib 5Specimen Handling 5Lenalidomide 5Bevacizumab 5130-nm albumin-bound paclitaxel 5tremelimumab 4niraparib 4cabozantinib 4amivantamab 4Prednisone 4Oxaliplatin 4Leucovorin 4Ipilimumab 4Fulvestrant 4Docetaxel 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Has announcements × idelalisib × Clear all
NCT02970318 2026-05-11

A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

Acerta Pharma BV

Phase 3 Active not recruiting
310 enrolled 18 charts 1 FDA
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04666038 2026-04-24

BRUIN CLL-321

Eli Lilly and Company

Phase 3 Active not recruiting
238 enrolled 17 charts 1 FDA
LymphoidOther hematologic neoplasm

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡